Drug Development
Arena Pharmaceuticals provides updates on obesity, insomnia drugs
Published in Obesity and Diabetes Week, April 24th, 2006
Arena recently received results from its chronic 12 and 6-month preclinical toxicology studies of APD356, its orally administered, internally discovered drug candidate for the treatment of obesity. The toxicology studies did not demonstrate any apparent drug effect on heart valves or pulmonary vasculature, and Arena continues to expect to initiate the APD356 phase III program in the second half of 2006.
"We are very encouraged by the results of these...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Epidemiology
ADIPOR2 variants have a minor contribution to diabetes risk - Diabetes Pathogenesis
MCHr1 deficiency raises insulin sensitivity in obese leptin-deficient, but not body weight - Diet & Nutrition
Casitas b-lineage lymphoma-deficient mice protected against obesity and diabetes - Obesity Complications
Obese-diabetic coronary artery bypass graft patients have high postoperative morbidity - Obesity Epidemiology
Variation in the adiponutrin gene influences its expression and is linked to obesity - Alzheimer Disease
Increased cortical atrophy in type 2 diabetes mellitus may increase Alzheimer disease risk - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
